AnaSpec Introduces new SensoLyte™ Beta-Secretase Assay Kit
Product News Jun 21, 2007
AnaSpec has introduced the SensoLyte™ 520 Beta-Secretase Assay Kit.
Beta-secretase catalyzes a key step in the production of beta-amyloid peptides seen accumulated in senile plagues of Alzheimer’s disease (AD) brains.
In order to facilitate high throughput screening of AD drug candidates, the company has developed SensoLyte™ 520 beta-secretase assay kit using a fluorescence resonance energy transfer (FRET) peptide, HiLyte Fluor™ 488-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(QXL™ 520)-OH.
The sequence of this FRET peptide is derived from the beta-secretase cleavage site of beta-amyloid precursor protein (APP) with Swedish mutation. This mutation enhances the susceptibility of APP to beta-secretase and results in an early onset of AD.
According to AnaSpec, this assay has sensitivity (0.03 mU/ml) with a signal-to-background ratio >10 after a 30-minute incubation. This homogeneous assay can be used to continuously monitor product formation. Validated with known inhibitors, the IC50 value for one of the inhibitors determined with SensoLyte™ 520 beta-secretase assay kit was consistent with published data.